Collaboration with National University Hospital Singapore
08 August, 2019: Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the commencement of a clinical validation collaboration with National University Hospital (NUH), a leading public teaching hospital in Singapore.
The aim of the clinical study is to validate Invitrocue’s Onco-PDO drug screening assay, which tests chemotherapy drugs on patient-derived organoids grown from the patient’s own tumour cells for patients with refractory solid tumours. The goal is to personalise cancer treatment by selecting chemotherapy drugs that will have the highest response rate for the individual patient.
NUH-Collaboration-2019
